Status:
RECRUITING
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Iodine-resistant Thyroid Cancer
Meningioma
Eligibility:
All Genders
18-90 years
Phase:
EARLY_PHASE1
Brief Summary
The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. Integri...
Detailed Description
This research has conducted extensive studies on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI. The same protocol had demonstr...
Eligibility Criteria
Inclusion
- histologically confirmed various cancer patients;
- 68Ga-TATE-RGD and 18F-FDG PET/CT within a week;
- signed written consent.
Exclusion
- known allergy against TATE-RGD;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06632860
Start Date
August 1 2024
End Date
December 30 2025
Last Update
July 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 010100